"Vaccines, Combined" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Two or more vaccines in a single dosage form.
| Descriptor ID |
D017778
|
| MeSH Number(s) |
D20.215.894.815
|
| Concept/Terms |
Vaccines, Combined- Vaccines, Combined
- Combined Vaccines
- Vaccines, Combination
- Combination Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Vaccines, Combined".
Below are MeSH descriptors whose meaning is more specific than "Vaccines, Combined".
This graph shows the total number of publications written about "Vaccines, Combined" by people in this website by year, and whether "Vaccines, Combined" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 11 | 11 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vaccines, Combined" by people in Profiles.
-
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years. JAMA. 2024 02 06; 331(5):408-416.
-
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial. J Infect Dis. 2023 12 20; 228(12):1662-1666.
-
Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine. Cell Rep Med. 2023 11 21; 4(11):101258.
-
Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients. JAMA Netw Open. 2023 10 02; 6(10):e2337602.
-
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial. Clin Infect Dis. 2023 08 22; 77(4):560-564.
-
Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023. MMWR Morb Mortal Wkly Rep. 2023 Aug 18; 72(33):886-892.
-
Development of chimeric protein as a multivalent vaccine for human Kinetoplastid infections: Chagas disease and leishmaniasis. Vaccine. 2023 08 23; 41(37):5400-5411.
-
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep. 2023 May 26; 72(21):579-588.
-
Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial. Vaccine. 2023 04 17; 41(16):2716-2722.
-
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 17; 71(53):1637-1646.